Outlook Therapeutics (OTLK) Change in Accured Expenses (2015 - 2026)
Outlook Therapeutics (OTLK) reported Change in Accured Expenses of $4.4 million for Q1 2026, up 541.08% year-over-year from $684384.2 in Q1 2025, and up 1582.48% quarter-over-quarter from -$295952.0 in Q4 2025.
Outlook Therapeutics (OTLK) Change in Accured Expenses (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Change in Accured Expenses data on file, last reported at $4.4 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at $4.4 million, up 541.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 million (up 1059.8% YoY), and the FY2025 annual result was $1.7 million, up 247.79% from the prior year.
- Change in Accured Expenses improved to $4.4 million in Q1 2026 per OTLK's latest filing, from -$295952.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $5.0 million in Q4 2022 and troughed at -$5.6 million in Q3 2023.
- A 5-year average of $276468.7 and a median of -$152635.0 in 2022 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses tumbled 3543.58% in 2023, then soared 638.75% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at $5.0 million in 2022, then slumped by 73.21% to $1.3 million in 2023, then slumped by 88.53% to $153764.0 in 2024, then plunged by 292.47% to -$295952.0 in 2025, then surged by 1582.48% to $4.4 million in 2026.
- Business Quant data shows OTLK's Change in Accured Expenses at $4.4 million in Q1 2026, -$295952.0 in Q4 2025, and $354702.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 | 4.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.39 Mn |
| Mar 31, 2026 | 4.39 Mn |
| Dec 31, 2025 | -295,952.00 |
| Dec 31, 2025 | -295,952.00 |
| Sep 30, 2025 | 354,702.00 |
| Sep 30, 2025 | 354,702.00 |
| Jun 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | -994,707.00 |
| Mar 31, 2025 | -994,707.00 |
| Dec 31, 2024 | 153,764.00 |
| Dec 31, 2024 | 153,764.00 |
| Sep 30, 2024 | 556,554.00 |
| Sep 30, 2024 | 556,554.00 |
| Jun 30, 2024 | -407,694.00 |
| Jun 30, 2024 | -407,694.00 |
| Mar 31, 2024 | -998,162.00 |
| Mar 31, 2024 | -998,162.00 |
| Dec 31, 2023 | 1.34 Mn |
| Dec 31, 2023 | 1.34 Mn |